What's Happening?
The rapid expansion of cell and gene therapies is challenging traditional regulatory frameworks, prompting a shift towards digital orchestration in the biopharmaceutical industry. Monika Birdi, a global product strategy leader at SAP, discusses the need
for a new digital infrastructure that supports the unique requirements of these therapies. Unlike traditional batch manufacturing, cell and gene therapies are patient-specific, necessitating precise coordination across clinical, manufacturing, and quality domains. The SAP Cell and Gene Therapy Orchestration platform aims to address these challenges by ensuring chain-of-identity and chain-of-custody, critical for compliance and operational efficiency. This approach integrates validation, traceability, and cross-system integration, essential for the global commercialization of advanced therapies.
Why It's Important?
The shift towards digital orchestration in cell and gene therapy is crucial for maintaining compliance and operational efficiency in a rapidly evolving field. As these therapies become more prevalent, the ability to manage complex supply chains and regulatory requirements is essential for ensuring patient safety and treatment efficacy. The implementation of digital frameworks can reduce compliance risks, streamline operations, and facilitate the global distribution of therapies. This transformation also highlights the broader trend of digitalization in the life sciences, which could lead to more efficient and scalable healthcare solutions.
